Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2018-07

    • Z-LEHD-FMK: Selective Caspase-9 Inhibitor for Apoptosis A...

    2026-04-01

    Z-LEHD-FMK: Selective Caspase-9 Inhibitor for Apoptosis Assays

    Principle and Setup: Z-LEHD-FMK as a Precision Tool for Apoptosis Research

    Apoptosis, or programmed cell death, is fundamental to both physiological homeostasis and disease pathogenesis. At the heart of the intrinsic (mitochondria-mediated) apoptosis pathway lies caspase-9, the initiator caspase that commits cells to death by orchestrating the caspase cascade. Z-LEHD-FMK (CAS 210345-04-3), supplied by APExBIO, is a selective and irreversible caspase-9 inhibitor. This apoptosis research compound is chemically engineered as an irreversible peptide inhibitor, binding covalently to the active site of caspase-9, thereby preventing downstream activation of executioner caspases such as caspase-3 and caspase-7. Through this mechanism, Z-LEHD-FMK enables precise modulation of the intrinsic apoptosis pathway, making it an essential reagent for experiments focused on caspase pathway modulation, cancer cell apoptosis, neuroprotection, and cytoprotective studies in various disease models.

    Z-LEHD-FMK exhibits high selectivity and stability, with solubility exceeding 107 mg/mL in DMSO and 98 mg/mL in ethanol. This makes it an ideal DMSO soluble apoptosis inhibitor for both in vitro and in vivo studies, including apoptosis assays, caspase activity measurement, and neurodegenerative disease models. Its efficacy in modulating mitochondria-mediated apoptosis has been demonstrated in a range of cell types, including HCT116 colon cancer cells, HEK293 cells, and hepatocytes, as well as in vivo models of spinal cord injury and ischemia/reperfusion injury.

    Experimental Workflow: Step-by-Step Protocol Enhancement with Z-LEHD-FMK

    1. Stock Solution Preparation

    • Weighing and Dissolving: Begin by weighing Z-LEHD-FMK powder under aseptic conditions. Dissolve in DMSO to achieve a stock concentration of ≥10 mM. For optimal dissolution, gently warm the DMSO solution (up to 37°C) and sonicate in an ultrasonic bath.
    • Aliquoting and Storage: Dispense into aliquots to avoid repeated freeze-thaw cycles. Store aliquots at ≤-20°C. Protect from light and use within 2-4 weeks for maximum potency. Avoid aqueous solutions until immediately prior to experimental use.

    2. Apoptosis Assay Setup

    • Cell Treatment: Add Z-LEHD-FMK to cell culture media at the desired working concentration (typically 10–50 μM), ensuring the final DMSO concentration does not exceed 0.1–0.5% v/v to minimize cytotoxicity.
    • Timing: Pre-treat cells with Z-LEHD-FMK for 30–60 minutes before apoptosis induction (e.g., TRAIL, staurosporine, or graphene film exposure as in the graphene-induced melanoma apoptosis study).
    • Controls: Always include DMSO-only and untreated controls. For mechanistic validation, compare with other caspase inhibitors (e.g., Z-DEVD-FMK for caspase-3).

    3. Downstream Assays

    • Caspase Activity Measurement: Quantify caspase-9 and downstream caspase-3/7 activity using fluorometric or luminescent substrates. Expect a >80% reduction in caspase-9 activity in Z-LEHD-FMK-treated samples, with corresponding decreases in apoptosis markers such as PARP cleavage and DNA fragmentation.
    • Phenotypic Readouts: Assess cell viability (MTT, CellTiter-Glo), apoptosis (Annexin V/PI staining), and colony formation. In published studies, Z-LEHD-FMK reduces TRAIL-induced cytotoxicity by 40–70% in sensitive cell lines and preserves neuronal integrity in animal models post-injury.

    4. In Vivo Administration

    • Preparation: Dissolve Z-LEHD-FMK in DMSO, then dilute with phosphate-buffered saline (PBS) immediately prior to injection. Ensure DMSO does not exceed 5% v/v in the final formulation.
    • Dosage: Typical in vivo dosing ranges from 0.5–2 mg/kg, administered intraperitoneally or locally, depending on model and endpoint.
    • Monitoring: Evaluate neuroprotection (e.g., reduced TUNEL-positive cell counts in spinal cord injury), organ function, and behavioral outcomes.

    Advanced Applications and Comparative Advantages

    1. Cancer Research and Apoptosis Modulation

    Selective caspase-9 inhibition by Z-LEHD-FMK enables dissection of the intrinsic apoptosis pathway in cancer models. In Zhao et al. (2023), Z-LEHD-FMK was used to verify the mitochondria-mediated apoptosis induced by graphene in B16F10 melanoma cells. The inhibitor rescued a significant proportion of apoptotic cells, confirming caspase-9’s pivotal role in this pathway. Such mechanistic validation is essential for identifying new therapeutic strategies and for distinguishing between caspase-dependent and -independent cell death.

    In HCT116 colon cancer and hepatocyte models, Z-LEHD-FMK confers selective cytoprotection, reducing apoptosis by up to 65% following TRAIL challenge. This supports its utility as a TRAIL-induced apoptosis inhibitor and for studying cancer cell apoptosis modulation.

    2. Neuroprotection in Spinal Cord and Ischemia/Reperfusion Injury

    In vivo, Z-LEHD-FMK demonstrates potent neuroprotection in rat models. Post-injury administration reduces apoptotic cell counts by 50–70% and preserves both neuronal and glial integrity, making it a valuable neuroprotection agent and caspase inhibitor for neurodegenerative disease models. Its ability to modulate the caspase signaling pathway translates into improved tissue preservation and functional outcomes in models of spinal cord injury and ischemic brain insult.

    3. Extension to Novel Disease Models and Drug Screening

    Z-LEHD-FMK’s chemical structure (methyl (4S)-5-[[(2S)-1-[[(3S)-5-fluoro-1-methoxy-1,4-dioxopentan-3-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-5-oxopentanoate) and irreversible binding mode make it ideally suited for high-throughput apoptosis assays and for screening candidate neuroprotective or cytoprotective compounds. Its quantitative inhibition profile supports robust, reproducible results across varied cell culture and animal paradigms.

    4. Relationship to Existing Literature

    Troubleshooting and Optimization Tips

    • Solubility Issues: If Z-LEHD-FMK fails to dissolve fully in DMSO, apply gentle heating (not exceeding 37°C) and sonication. Avoid direct dilution in aqueous buffers before complete dissolution.
    • Stock Stability: Limit freeze-thaw cycles by preparing small aliquots. Ensure storage at ≤-20°C, protected from moisture and light. Use stocks within one month for best results.
    • DMSO Cytotoxicity: Maintain final DMSO concentrations in cell culture ≤0.5%. Always include DMSO-only vehicle controls to distinguish compound effects.
    • Concentration Titration: Optimal working concentrations typically range from 10–50 μM in vitro. For sensitive lines or primary cultures, titrate to determine the minimum effective dose.
    • Assay Validation: Include positive (e.g., staurosporine-induced apoptosis) and negative controls (untreated, or using an inactive peptide analog) to confirm specificity of caspase-9 inhibition.
    • Off-target Effects: While Z-LEHD-FMK is a highly selective caspase-9 inhibitor, high concentrations may impact related caspases. Validate inhibition profiles using specific caspase activity kits and, if necessary, compare with structural analogs.

    Future Outlook: Expanding the Frontiers of Caspase Pathway Modulation

    As interest in apoptosis modulation grows—across oncology, neurodegeneration, and tissue engineering—Z-LEHD-FMK (SKU B3233) from APExBIO is poised for ever-broader utility. Its proven selectivity and robust performance in mitochondria-mediated apoptosis models support its adoption in next-generation platforms, from 3D organoids to high-content screening. Opportunities abound for integrating Z-LEHD-FMK into multiplexed caspase activity assays, live-cell imaging, and advanced in vivo models of cancer and neurodegenerative disease.

    Emerging evidence, such as the graphene-induced melanoma apoptosis study, highlights the compound’s critical role in validating novel therapeutic strategies and dissecting complex signaling pathways. As apoptosis research moves beyond classical models into precision medicine and combinatorial interventions, Z-LEHD-FMK remains a cornerstone for mechanistic discovery and translational innovation.

    For detailed protocols, ordering information, and technical support, visit the official Z-LEHD-FMK product page at APExBIO.